Anti-YAP1 (phospho Y357) antibody (ab62751)

ab62751 has been referenced in 8 publications.

• Papaspyropoulos A  et al. RASSF1A uncouples Wnt from Hippo signalling and promotes YAP mediated differentiation via p73. Nat Commun 9:424 (2018). PubMed: 29382819
• Sourbier C  et al. Targeting loss of the Hippo signaling pathway in NF2-deficient papillary kidney cancers. Oncotarget 9:10723-10733 (2018). PubMed: 29535838
• Miao J  et al. YAP regulates PD-L1 expression in human NSCLC cells. Oncotarget 8:114576-114587 (2017). WB . PubMed: 29383103
• Abe M  et al. STAT3 deficiency prevents hepatocarcinogenesis and promotes biliary proliferation in thioacetamide-induced liver injury. World J Gastroenterol 23:6833-6844 (2017). PubMed: 29085226
• Taniguchi K  et al. YAP-IL-6ST autoregulatory loop activated on APC loss controls colonic tumorigenesis. Proc Natl Acad Sci U S A 114:1643-1648 (2017). PubMed: 28130546
• Rizvi S  et al. A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in Cholangiocarcinoma. J Biol Chem 291:8031-47 (2016). PubMed: 26826125
• Pijuan-Galitó S  et al. Serum Inter-a-inhibitor activates the Yes tyrosine kinase and YAP/TEAD transcriptional complex in mouse embryonic stem cells. J Biol Chem 289:33492-502 (2014). PubMed: 25301940
• Liu X  et al. PTPN14 interacts with and negatively regulates the oncogenic function of YAP. Oncogene : (2012). PubMed: 22525271